Who else want­ed to buy Iver­ic? Be­fore the $5.9B Astel­las deal, five bio­phar­ma com­pa­nies took a look

Two years ago, as Iver­ic Bio went through late-stage stud­ies of its main ex­per­i­men­tal drug, it be­gan at­tract­ing in­ter­est from po­ten­tial buy­ers. Five com­pa­nies end­ed up in ear­ly-stage dis­cus­sions with the biotech at the time, and oth­ers would ex­press in­ter­est lat­er on, though ul­ti­mate­ly, on­ly one would make a bid to buy it.

Iver­ic end­ed up strik­ing a $5.9 bil­lion deal with Astel­las in April. An SEC fil­ing de­tails the run-up to the takeover, show­ing Astel­las was the sole for­mal bid­der on Iver­ic de­spite draw­ing gen­er­al in­ter­est from a hand­ful of bio­phar­mas. Iver­ic’s key drug, called Zimu­ra or avac­in­cap­tad pe­gol, is up for an FDA ap­proval de­ci­sion in Au­gust to treat ge­o­graph­ic at­ro­phy, a se­ri­ous eye dis­ease that can lead to blind­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER